Sandbox/v12: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
Line 1: Line 1:
======Community-acquired meningitis======
======Community-Acquired Meningitis======


{|
{|
Line 23: Line 23:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q12h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q12h'''''
|-
|-
|}
<BR>
<BR>
<BR>
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age 1—4 Weeks}}''
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age 1—4 Weeks}}''
|-
|-
Line 58: Line 53:
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 225–300 mg/kg per day IV q6–8 h''''' <BR>''OR''<BR>▸ '''''[[Ceftriaxone]] 80–100 mg/kg per day IV q12–24 h'''''<sup>¤</sup>
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 225–300 mg/kg per day IV q6–8 h''''' <BR>''OR''<BR>▸ '''''[[Ceftriaxone]] 80–100 mg/kg per day IV q12–24 h'''''<sup>¤</sup>
|-
|}
<BR>
<BR>
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age 2–50 years}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Children's dosage is as shown left,shown below is the adult'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin ]] 30–60 mg/kg per day IV8–12 h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]  8–12 g per day IVq4–6h '''''<BR> ''OR''<BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12 h'''''<sup>¤</sup>
|-
|}
<BR>
<BR>
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Age >50 years}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin ]] 30–60 mg/kg per day IV8–12 h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]  8–12 g per day IV q4–6h '''''<BR> ''OR''<BR>▸''''[[Ceftriaxone]] 2 g IV q12 h'''''
|-
|-
|}
|}
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:19em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Recurrent}}''
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Immunocompromised state}}''
|-
|-




! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin ]] 30–60 mg/kg per day IV 8–12 h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]]  2 g IV q4 h '''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]]  2 g IV q8 h''''' <BR> ''OR'' <BR> ▸'''''[[Meropenem]]  2 g IV q8 h'''''
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Recurrent}}''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
Line 76: Line 118:
|}
|}
| valign=top |
| valign=top |
|}
|}



Revision as of 18:02, 14 January 2014

Community-Acquired Meningitis
Age <1 Week
Preferred Regimen
Ampicillin 50 mg/kg IV q8h
AND
Cefotaxime 100—150 mg/kg/day IV q8—12h
Alternative Regimen
Ampicillin 50 mg/kg IV q8h
AND
Gentamicin 2.5 mg/kg IV q12h
Age 1—4 Weeks
Preferred Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Cefotaxime 150—200 mg/kg/day IV q6—8h
Alternative Regimen
Ampicillin 200 mg/kg/day IV q6—8h
AND
Gentamicin 2.5 mg/kg IV q8h
OR
Tobramycin2.5 mg/kg IV q8h
OR
Amikacin 10 mg/kg IV q8h
Age 1—23 Months
Preferred Regimen
Vancomycin 15 mg/kg IV q6 h
AND
Cefotaxime 225–300 mg/kg per day IV q6–8 h
OR
Ceftriaxone 80–100 mg/kg per day IV q12–24 h¤



Age 2–50 years
Preferred Regimen
Children's dosage is as shown left,shown below is the adult
Vancomycin 30–60 mg/kg per day IV8–12 h
AND
Cefotaxime 8–12 g per day IVq4–6h
OR
Ceftriaxone 2 g IV q12 h¤



Age >50 years
Preferred Regimen
Vancomycin 30–60 mg/kg per day IV8–12 h
AND
Cefotaxime 8–12 g per day IV q4–6h
OR
▸'Ceftriaxone 2 g IV q12 h
Immunocompromised state
Preferred Regimen
Vancomycin 30–60 mg/kg per day IV 8–12 h
AND
Ampicillin 2 g IV q4 h
AND
Cefepime 2 g IV q8 h
OR
Meropenem 2 g IV q8 h
Recurrent
Preferred Regimen
Vancomycin 30–60 mg/kg per day IV8–12 h
AND
Cefotaxime 8–12 g per day IVq4–6h
OR
▸'Ceftriaxone 2 g IV q12 h


¤Add amoxicillin or ampicillin if meningitis caused by L monocytogenes is also suspected. Ampicillin if meningitis caused by L monocytogenes is also suspected